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To date, the development of bioreactors for the study of red blood cells (RBCs,
daily transfused in the case of disease or hemorrhage) has focused on hematopoietic
stem cells. Despite the fact that mature RBCs are enucleated and do not expand,
they possess complex cellular and metabolic pathways, as well as post-translation
modification signaling and gas-exchange regulation. In order to dynamically study the
behavior of RBCs and their signaling pathways under various conditions, a small-scale
perfusion bioreactor has been developed. The most advanced design developed here
consists of a fluidized bed of 7.6 mL containing 3·109 cells and perfused at 8.5 µL/min.
Mimicking RBC storage conditions in transfusion medicine, as a proof-of-concept, we
investigated the ex vivo aging of RBCs under both aerobic and anaerobic conditions.
Hence, RBCs stored in saline-adenine-glucose-mannitol (SAGM) were injected in parallel
into two bioreactors and perfused with a modified SAGM solution over 14 days at room
temperature under air or argon. The formation of a fluidized bed enabled easy sampling
of the extracellular medium over the storage period used for the quantitation of glucose
consumption and lactate production. Hemolysis and microvesiculation increased during
aging and were reduced under anaerobic (argon) conditions, which is consistent with
previously reported findings. Glucose and lactate levels showed expected trends, i.e.,
decreased and increased during the 2-week period, respectively; whereas extracellular
glucose consumption was higher under aerobic conditions. Metabolomics showed
depletion of glycolsis and pentose phosphate pathwaymetabolites, and an accumulation
of purine metabolite end-products. This novel approach, which takes advantage of a
fluidized bed of cells in comparison to traditional closed bags or tubes, does not require
agitation and limit shear stress, and constantly segragates extracellular medium from
RBCs. It thus gives access to several difficult-to-obtain on- and off-line parameters in the
extracellular medium. This dynamic bioreactor system does not only allow us to probe the
behavior of RBCs under different storage conditions, but it also could be a powerful tool
to study physiological or pathological RBCs exposed to various conditions and stimuli.
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INTRODUCTION
Red blood cells (RBCs) are specific cells that are devoid of nuclei
and mitochondria and are not able to replicate in their mature
state (erythrocytes). They are essential, and in case of hemorrhage
or disease, they can be transfused from stored erythrocyte
concentrates (ECs). In several recent clinical studies in cardiac
surgery and intensive care unit patients, the quality of ECs has
been questioned (Koch et al., 2008; Lacroix et al., 2015; Steiner
et al., 2015), as different outcomes were observed, feeding the
debate (Benjamin and Dodd, 2008; McCullough, 2013; Zimring,
2013; van de Watering, 2013a,b, 2014; Prudent et al., 2015). A
large controversy has thus emerged in the transfusion medicine
community: not only long-term-stored ECs are presented as
biomedical products of lesser efficiency, but also tend to be
viewed as harmful therapeutic interventions (Hod et al., 2011;
Hod and Spitalnik, 2012; Rubin et al., 2013; Danesh et al., 2014).
During storage, RBCs suffer from storage lesions (Tinmouth
and Chin-Yee, 2001; Hess and Greenwalt, 2002; Prudent et al.,
2011; Flatt et al., 2014; D’Alessandro et al., 2015), i.e., molecular
and cellular modifications of RBCs during blood banking. Firstly,
in vitro studies have shown the increase of hemolysis (depending
on the additive solutions, AS, and the preparation processes)
and accumulation of microvesicles (MVs) (Rubin et al., 2008;
Sparrow et al., 2014), the loss of metabolic modulation (e.g.,
adenosine triphosphate, ATP, and 2,3-bisphosphoglycerate, 2,3-
DPG, depletion) and pH lowering (Hess et al., 2000; Bennett-
Guerrero et al., 2007; Sparrow et al., 2014). Secondly, at the
protein level these modifications include the aggregation and
degradation of the band 3 protein generating the formation of
neoantigens (Bosman et al., 2008), and alteration of proteins
(D’Amici et al., 2007; Bosman et al., 2008; Antonelou et al.,
2010; Rinalducci et al., 2011; Delobel et al., 2012, 2016; Pallotta
et al., 2015). The metabolism plays a central role regulating
several ATP-dependent enzymes, antioxidant defenses and other
cellular functions. For instance, band 3 complexes regulate the
RBC metabolism (Chu et al., 2008; Lewis et al., 2009) and
the gas-exchange (Bruce et al., 2003) required to deliver O2 to
tissues and organs. Metabolomic studies have reported a decrease
in glycolysis rate and the accumulation of lactate but some
differences were observed in other pathways such as the pentose
phosphate pathway (PPP) (Nishino et al., 2009; Gevi et al.,
2012; Paglia et al., 2014; Roback et al., 2014). This metabolomic
approach was also applied to the study of new storage conditions,
such as anaerobic conditions (D’Alessandro et al., 2013) or new
AS compositions (Nishino et al., 2013). Even though RBCs are
able to counterbalance the lesions during cold storage, they are
not able to totally stop the reversible degradation that is the
prelude to irreversible lesions. Current knowledge of storage
lesions and RBC aging mechanisms has to expand to improve
RBC storage conditions and to better understand the links to
Abbreviations: 2,3-DPG, 2,3-bisphosphoglycerate; AS, additive solution; ATP,
adenosine triphosphate; ECs, erythrocyte concentrates; GSH, glutathione; Hb,
hemoglobin; LC, liquid chromatography; RBCs, red blood cells; MS, mass
spectrometry; mSAGM, modified SAGM; MVs, microvesicles; PCA, Principal
component analysis; PPP, pentose phosphate pathway; RT, room temperature;
SAGM, saline-adenine-glucose-mannitol.
adverse clinical outcomes that may participate in pro-thrombotic
events (Jy et al., 2013; Rubin et al., 2013) and inflammatory effects
(Hod et al., 2011; Hod and Spitalnik, 2012; Danesh et al., 2014).
Myriad solutions can be considered to reduce storage lesions.
The addition of antioxidants (such glutathione, GSH, or ascorbic
acid) or precursor of the GSH synthesis prevents oxidative
stress (ascorbic acid and N-acetylcysteine) (Dumaswala et al.,
2000; Pallotta et al., 2014), but decrease the energy metabolism
(Pallotta et al., 2014). Another approach is the storage under
anaerobic conditions. The principle of anaerobic storage is
quite trivial and consists of replacing O2 by an inert gas such
as helium or argon. Zolla and colleagues stored RBCs under
helium to protect the cells against oxidative stress and observed
reduced protein degradation (D’Amici et al., 2007). To ensure
the complete depletion, Yoshida and colleagues developed a
system where, first, the O2 was depleted by argon, and second,
the ECs were placed in an anaerobic canister filled with Ar/H2
(9/1). Importantly, this canister contained a palladium catalyst
that guaranteed depletion during storage (Yoshida et al., 2007;
Dumont et al., 2009; Yoshida and Shevkoplyas, 2010). Using
this system, they significantly improved the ATP level, but not
2,3-DPG, during RBC storage (2-fold after 63 days) and could
push the storage limit up to 9 weeks (vs. 6 weeks for storage
in permeable bags containing saline-adenine-glucose-mannitol,
SAGM) (Yoshida et al., 2007). They also observed a decrease in
microvesiculation, demonstrating a benefit to RBC membranes.
Regarding metabolomics, glycolysis was enhanced (Kinoshita
et al., 2007; Lewis et al., 2009; D’Alessandro and Zolla, 2013).
However, under these conditions, the shift to the PPP was
partially blocked, thus reducing the glutathione-based defenses
(less glutathione and increased level of oxidized glutathione)
and attenuating the effect of anaerobic storage (Dumont et al.,
2016). Interestingly, the effect of anaerobic storage on carbon
monoxide-exposed RBCs on ATP was suppressed, which is well
in phase with the Kinoshita and colleagues’ work (Kinoshita et al.,
2007). These results are in agreement with the known regulation
of O2-dependent glycolysis (Chu et al., 2008). While intriguing,
the aforementioned studies have worked directly on ECs and
have required sample preparation prior to analyses.
Research on ECs and RBC aging has long been empirical
in transfusion medicine where blood bags or freshly withdrawn
blood are used. Solid in vitro in addition to in vivo data are
required to understand the lesions and to target development
(Hess, 2006; Prudent et al., 2015). There is a clear unmet
need for a dynamic bioreactor which requires fewer samples
and less biological sampling, whereas the main developments
were dedicated to stirred, fixed-bed or hollow fibers bioreactors
for hematopoietic stem cells (Collins et al., 1998; Liu et al.,
2006; Timmins et al., 2011; Housler et al., 2012; Ratcliffe et al.,
2012). The only published system of mature RBC bioreactor is
a closed stirred-tank reactor, enabling gas regulation (Deonikar
and Kavdia, 2010). However, numerous solutions are available
to segregate cells to a confined space for the purpose of
studying their behavior (Butler, 2005; Zhong, 2010). Jolicoeur
and colleagues have designed small-scale bioreactors for the
culture of plant and mammalian cells (Gmati et al., 2005; Ben-
Tchavtchavadze et al., 2010). A similar approach was applied
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here to develop a small-scale bioreactor of RBCs, taking into
account the size and deformability of these cells. The aims of the
proposed system were to (i) design a small bioreactor capable of
segregating RBCs from medium, providing nutrients, allowing
sampling and/or on-line monitoring in the supernatant; and (ii)
to study RBC aging and different storage conditions. In future,
this device could be a valuable tool to study cellular pathways
under various conditions.
MATERIALS AND METHODS
Chemicals
NaCl, adenine andmannitol were purchased from Sigma-Aldrich
(Steinheim, Germany); ethanol 70% from Fluka analytical
(Buchs, Switzerland); and glucose from Merck (Darmstadt,
Germany). Physiological 0.9% NaCl was purchased from B.
Braun Medical (Sempach, Switzerland) and PBS 10x from
Laboratorium Dr. Bichsel (Interlaken, Switzerland). H2O used
for each solution was deionized water at 18.2M·cm.
Modified SAGM (mSAGM) was prepared as follows: 150mM
NaCl, 1.2M adenine, 4.5mM glucose, and 30mM mannitol, and
the solution was filtered at 0.22 µm and stored at 4◦C.
Preparation of Erythrocyte Concentrates
ECs were prepared from whole blood donations of 450 ± 50
mL in citrate-phosphate-dextrose anticoagulant and component
filtered (Delobel et al., 2012). ECs were stored at 4◦C in SAGM at
a hematocrit of 0.6 ± 0.1 v/v. ECs that did not meet the quality
criteria for blood transfusion, e.g., low hemoglobin content or a
slightly too small volume, were used under the signed consent of
blood donors. No research on genetic material was carried out.
Therefore, no specific ethical processing was required and these
samples were used in agreement with the local legislation.
Small-Scale Perfusion Bioreactor
Design
Several designs were considered to properly confine RBCs
(see Supplementary Figure 1) and the following represents
the most advanced design. Each bioreactor includes (see
Figure 1) a chamber (20mL-syringe barrel cut at 15mL-grad.
line, Omnifix, B-Braun, Ë), with qualitative paper filter at
the bottom (held by two 20mL-syringe plunger half rings,
Omnifix, B-Braun) to ensure homogenous flow and retain cells
before the flow was switched on, a rubber cap (Suba Seal
Septa 37, Aldrich), a capillary and luer connectors (BioRad)
to interface with the tubing; a reservoir (20mL-syringe barrel
cut at 8mL-graduation line, Omnifix, B-Braun, Ì), with a
stirring magnet to ensure medium homogeneity, a rubber cap,
and luer connectors to interface with the tubing. The flow
rate was applied using a 4-channel peristaltic pump (Reglo
Digital MS-4/8, Ismatec, Ê) capable of running two bioreactors
in parallel (2 channels/bioreactor, 1 from the chamber to the
reservoir and 1 from the reservoir to the chamber) using tubing
for carrying bioreactor medium (Tygon R3607, Saint Gobain
FIGURE 1 | Small-scale perfusion bioreactor of RBCs. Medium (mSAGM) was pumped (Ê) at 8.5 µL/min from the reservoir (Ì) to the chamber (Ë) to fluidize
RBCs and then pumped back to the reservoir. Gas (air or argon) was supplied to both the chamber and the reservoir, through a humidifier (Í). Sampling was done in
the reservoir using a sterile needle through the rubber cap (Í). pH and K+ probes can be easily fitted to the reservoir.
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Performance Plastics). Different gases (compressed air 2.2 and
argon 5.0, Messer, Switzerland) filled the chamber and the
reservoir through gas tubing (Tygon ID = 1.6mm, Saint Gobain
Performance Plastics), with filters (25mm syringe filter, 0.2 µm
polyethersulfone membrane, VWR), syringe needles (Neolus,
1.2 × 40mm, Terumo) as interface tubing-chamber/reservoir,
luer and 0.8mm T-connectors (BioRad). H2O-containing gas
humidifier chambers (Í) were added to avoid drying the system
and a gas evacuation and control chambers (20mL syringe, B-
Braun, Î), with open vents and filled with H2O to check correct
gas circulation (constant bubbling, ∼2–3 bubbles/s) in every
compartment.
Bioreactor Storage Experiments
Two bioreactors were run in parallel under a specific gas
condition (air 2.2 or argon 5.0, i.e., aerobic or anaerobic
conditions, respectively) during 2 weeks. First, each system was
filled with 7mL of mSAGM solution (5mL in chambers, 2mL
in reservoirs) and 0.6mL from an EC was gently loaded into
each chamber with a 1mL syringe (Omnifix, B-Braun). Then,
the gas supplies were opened, and the magnetic stirrer and the
peristaltic pump turned on. The pump ensured a constant low-
flow (8.5µL/min)medium circulation between the chambers and
the reservoirs, and the maintenance of the RBCs fluidized bed
with the resulting bottom-up medium flow into the chambers.
Antibiotics (penicillin and streptomycin) were also added (see
“Discussion”). After 14 days, the system was stopped. Before and
after each experiment, the whole system was cleaned out with
soap in H20, ethanol 70%, and finally rinsed with H20.
The bioreactor storage experiments were repeated three times
on ECs (at 4, 6, and 7 days of storage) originating from three
different donors.
Sampling
ThreemL of an EC was aseptically withdrawn at day 0. Two
samples of 0.6mL from it were loaded in the bioreactors,
15 µL were used for MV counting and 50 µL for hemolysis
measurement. Then, the supernatant was collected after
centrifugation at 2000 g, 10min, 4◦C and stored at −28◦C for
hemolysis measurements. RBCs were washed two times in 0.9%,
NaCl and stored at −28◦C (aliquot of 100 µL of packed RBCs)
for intracellular metabolite quantification.
At 2–3 days intervals, a 20 µL sample was removed from each
reservoir (Ï) using a 1-mL sterile syringe and a sterile needle,
and stored at−28◦C for further testing (extracellular glucose and
lactate concentrations).
At the end of the experiment, the whole content of the
bioreactors (medium and cells) was removed and pooled. As
day 0 sample, 15 µL of these bioreactor total samples were used
for MV counting and 50 µL for hemolysis measurement.
RBCs and supernanants were prepared and stored as
before.
Hemolysis, MVs and Metabolite Analyses
The hemolysis rate was measured on pre-/post-bioreactor
samples. Hemoglobin concentration ([Hb]total) and hematocrit
were obtained with an automated hematology analyzer (KX-
21N, Sysmex) from 50 µL of EC and the free hemoglobin
concentration in the supernatant ([Hb]supernatant) was
determined by the Harboe method by measuring the absorbance
at 415, 380, and 450 nm with a spectrophotometer (UltroSpec
1000, Pharmacia Biotech) (Harboe, 1959) as follows:
[
Hb
]
supernatant
=
(167.2A415 − 83.6 (A380 + A450)) .
dilution factor
1000
(1)
where A stands for the absorbance at different wavelength.
The hemolysis rate in % was obtained with the following
equation:
Hemolysis =
[Hb]supernantant · (100− hematocrit)
[Hb]total
(2)
The MV concentration was quantified by flow cytometry in
pre-/post-bioreactor samples (Delobel et al., 2012). Five micro
liter of samples were incubated in triplicate with 5 µL FITC
mouse anti-human CD47 antibody and incubated 20min at
room temperature (RT) on a roller. Before analysis, 5 µL of
labeled MVs were dissolved in 400 µL of NaCl 0.9% into BD
Trucount tubes that contained a precise number of three-time
labeled microbeads for quantification.
Extracellular glucose and lactate concentrations were
determined from 10 and 4 µL of reservoir samples, respectively,
using colorimetric assays according to manufacture protocols
(Biochain glucose assay kit, Z5030025, Biochain; Biovision
lactate colorimetric assay II, K627-100, Biosion). Absorbances
were recorded on a spectrophotometer (Reader 2001, Anthos
Labtec Instruments) and the concentrations were calculated
from metabolite calibration curves.
Metabolomics
Intracellular metabolites were extracted from 100 µL pre-/post-
storage RBCs samples using a methanol extraction protocol. One
hundred microliters of ice-thawed RBCs were mixed with 300µL
of MeOH and sonicated 10min at RT. Three hundred microliters
of the supernatants were transferred to a 1.5mL tube after
centrifugation at 20,817 g, 12min, 4◦C. Metabolite extracts were
dried under N2 flux for 1 h at RT. Dried extracts were dissolved in
100 µL of ACN/H2O 50/50 (v/v), vortexed, sonicated for 10min
and stored on ice for 20min. After a final centrifugation (as
before), 80 µL of solution was transfer to an injection vial.
Four microliters of each sample were injected in triplicates
on an LTQ HPLC system (Thermo Scientific, Germany) with
a well-plate autosampler thermostated at 4◦C (HTS PAL
system, CTS Analytics, CH), Rheos pumps (Flux instruments,
Switzerland) and a thermostated column compartment.
Chromatographic separations were achieved onto a ZIC-pHILIC
column (100mm × 2.1mm, 5 µm—SeQuant R©, Germany) at
a column temperature of 40◦C. Chromatography conditions
are summarized in Table 1 (the buffer was made of ammonium
carbonate at 100mMpH9.2). High resolutionmass spectrometry
(MS) analysis was carried out on an Exactive PlusTM MS (Thermo
Scientific, Germany) equipped with an electrospray ionization
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TABLE 1 | LC gradient conditions.
# Time [min] H2O [%] ACN [%] Buffer [%] Flow rate [µL/min]
0 0 0 95 5 300
1 0.5 0 95 5 300
2 20 25 70 5 300
3 24 45 50 5 300
4 26 75 20 5 300
5 29 75 20 5 300
6 29.1 0 95 5 400
7 33.9 0 95 5 400
8 34 0 95 5 50
9 — 100 0 0 50
source (H-ESI-II). Mass spectra for metabolite extracted
samples were acquired in negative ionization mode. Instrument
calibration was performed externally every month with a Pierce R©
calibration solution (Thermo Scientific, Germany).
Xcalibur software (Thermo Scientific, Germany) was used for
data treatment. The mass extraction window was performed with
a range of ± 5 ppm and the peak integration parameters were
200 for the baseline window, 10 for the area noise factor and 50
for the peak noise factor. The progenesis-QI software (Non-linear
Dynamics Ltd, UK) was used to perform principal component
analysis (PCA) with the following parameters: MS profile data,
negative; peak picking: automatic sensitivity, minimum peak
width of 0.05min, normalized to all compounds; identification:
home-made database.
Statistical Analyses
t-test analyses were performed between hemolysis, MV count,
lactate and glucose levels in air or argon bioreactors using
the software R version 3.0.1 (The R foundation for Statistical
Computing). p-values lower than 0.05 were considered as
significant.
Metabolomic data were analyzed using the progenesis-QI
software as described in Section Metabolomics p-values lower
than 0.05 were considered as significant.
RESULTS
Bioreactor Conceptualization
Several designs of continuous reactors were investigated, such
as open or closed perfusion reactors using filters and fluidized-
bed reactors (see Supplementary Figure 1 for the tested designs).
Because of the RBC size (around 7 µm) and their ability to pass
through small pores of a few microns, the most suitable design
was a perfusion bioreactor with the fluidization of RBCs. The
flow rate was determined by achieving a distinct and flat layer
of RBCs, at 8.5 µL/min. Below this flow rate, the bed collapsed
with an accumulation of RBC in the input tube; and above, the
convection front continuously increased, where RBCs reached
the outlet and recirculated within the whole system. Recirculation
of RBCs generated hemolysis (0.7% after 8 passages through the
pump and 3.5% after 100 passages using 6 and 7-day old ECs with
an initial hemolysis of 0.07 and 0.08%, respectively).
Using an open system was not possible using the AS because
the low initial amount of plasma in the EC has been shown
necessary to maintain the cell integrity. Indeed, a clear hemolysis
(supernatant became clear red, a sign of hemolysis) was observed
at day 2 in open systems (inlet reservoir containing SAGM and
outlet to the waste) that was explained by washing the RBCs with
fresh AS. The remaining plasma inside the ECs was required to
limit hemolysis and it was observed that albumin levels as low as
5 g/L were sufficient to prevent RBC lysis (0.4% after 7 days at RT
in the presence of BSA at 5 g/L vs. 1.2% without BSA) in AS (see
Supplementary Materials and Supplementary Figure 2).
Therefore, the optimal design is illustrated in Figure 1, a
small-scale fluidized-bed bioreactor that contained 2.8·109 RBCs
in a total volume of 7.6mL of mSAGM. The system was stable
for at least 2 weeks but could be maintained for longer periods of
time (as at 4◦C for instance).
Hemolysis, MVs and Extracellular
Metabolites
The results for hemolysis and MVs are shown in Figure 2.
Absolute quantities instead of concentrations were used to take
into account the volume difference between the bioreactors.
Indeed, medium volume decreased in the bioreactors (∼10%,
due to evaporation by the gas flow despite the humidifiers), and
this decrease was not uniform in the two parallel bioreactors.
Thus, the results from the three experiments were pooled after
normalization.
Hemolysis [calculated from Equation (2)] reached a value of
1.8 ± 0.5% (air) and 1.4 ± 0.3% (argon) at day 14 (Figure 2A,
p < 0.01, n = 3) for an initial value of 0.12 ± 0.04% indicating a
lower hemolysis level under argon. MVs, that increase in number
during storage [24,700 ± 6700 MVs/µL at day 14 at RT in both
bioreactors against 33,700 ± 13,000 MVs/µL at day 42 under
current storage in EC bags (n = 3)], also exhibited lower count
under argon (Figure 2B).
The glucose profiles showed a small but constant decrease over
time (Figure 3A) and lactate concentrations typically increased
until day 7 before slowly diminishing (Figure 3B). Glucose
consumption was slightly lower under argon, whereas lactate
profiles were equivalent under both conditions. As expected, we
observed a substantial inter-donor variability. It should be also
noted that extracellular medium samples were taken at day 0 only
1 h after injection of RBCs, i.e., before medium homogenization
(RBCs were injected along with the solution contained in the EC,
whose composition differs from mSAGM). More than half a day
was required to renew the bioreactor volume (residence time,
as total volume/flow rate, of 14.9 h), resulting in gaps observed
between day 0 and day 2 in glucose concentrations.
Metabolomics
Fifty three intracellular metabolites were targeted by virtue of
their importance in the energy metabolism (e.g., ATP, NADH,
glucose) or in the cellular redox balance maintenance (e.g.,
GSH/GSSG, NADPH) of the RBCs. Other metabolites (e.g.,
amino acids) were also investigated. As the isomers ribose 5-
phosphate/ribulose 5-phosphate/xylose 5-phosphate could not
be distinguished by MS, they were grouped. The three types of
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FIGURE 2 | Hemolysis (A) and MV count (B) in function of storage conditions. Data were normalized to air conditions before averaging and are the mean
relative value ± standard deviation. Hemolysis was significantly lower under argon (*p < 0.017, n = 3). MV count was lower under argon but not significantly different
(p = 0.266, n = 3). ns stands for non-significant.
FIGURE 3 | Extracellular glucose consumption (A) and lactate production (B). Average results that were normalized to air day 2 conditions before averaging
and are the mean relative value ± standard deviation. As expected, glucose level decreased and lactate level increased during storage. Even though the consumption
of glucose was slightly higher under air condition, the difference is not significant (p > 0.1, n = 3). Lactate productions were equivalent under air or argon (p > 0.09,
n = 3).
samples: day 0, day 14 air and day 14 argon, were injected each
three times on the LC-MS.
PCA highlighted two distinct groups (Figure 4). The effect
of aging is clearly observed with a consequential shift in PC1,
whereas air and argon conditions at day 14 did not significantly
differ.
A few key metabolites of the glycolysis, the PPP and the
purine metabolism are depicted in Figure 5 (see Supplementary
Materials for detailed results). During storage there was
a clear depletion of glycolytic metabolites, except for
phosphoenolpyruvate that tended to accumulate. The decrease
in lactate was consistent with the increase in the extracellular
medium. A depletion was also observed in the oxidative
PPP and accompanied by an accumulation of metabolites in
purine metabolism such as hypoxanthine and xanthine. These
accumulations clearly indicated that an important part of the
purines were derivate to non-usable products for ATP synthesis.
Consequently, ATP was also depleted.
Metabolomic differences between air and argon conditions
were extensive. The fast depletion of metabolites in bioreactor
storage experiments at RT did not provide clear segregation of
FIGURE 4 | Principal component analysis of metabolomic data. RBC
aging inside the bioreactors was clearly assessed. Gray cloud represents
unidentified compounds. No data filters were used.
the data. Nevertheless, more ATP was consumed (or produced
in lower amounts) and less NADP was consumed under argon.
In addition to an accumulation of ribose 5-phosphate and
purine metabolites, it was hypothesized that non-oxidative PPP
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FIGURE 5 | Simplified overview of key RBC metabolites in the bioreactor storage experiments. Glycolytic and PPP metabolites were consumed during
ex vivo aging, whereas accumulations were observed in the purine metabolism. Data are expressed as fold-change compared to day 0. Bold arrows represent the
possible shunt from glycolysis to PPP under argon at RT. Glc, glucose; G6P, glucose 6-phosphate; FDP, fructose 1,6-biphosphate; 3PG, 3-phosphoglycerate; PEP,
phosphoenolpyruvate; Pyr, pyruvate; Lac, lactate; GL6P, 6-phosphogluconate; R5P, ribose 5-phosphate; PRPP, phosphoribosylpyrophosphate; HYP, hypoxanthine.
1, 2, and 3 are the bioreactor experiment numbers. *p < 0.05 compared to day 0, n = 3.
was promoted through the conversion of glucose 6-phosphate
to ribose 5-phosphate (Figure 5, bold arrow) (Stryer, 1992).
This pathway bypasses the production of ATP and NADPH.
Ribose 5-phosphate then enters the purine metabolism and it
can be either recycled to produce ATP or degraded through
xanthine and urate. This last pathway should pass through O2-
independent reaction in the argon bioreactor since the formation
of xanthine from hypoxanthine is catalyzed by xanthine oxidase
in an O2-dependent manner. Moreover, allantoin, an oxidized
product of urate, was less abundant in the RBCs under argon.
It must to be noted that experiments behaved slightly
differently each others. For instance, Experiment 2 exhibited
higher level of amino-acids under argon than under air (see
Supplementary Figure 3); and Experiment 3 showed depletion of
purine metabolites. The metabolomics reported here were end-
point experiments only and the kinetics during senescence is not
reported. Therefore, relative differences may be underestimated
since several metabolites were consumed during the bioreactor
storage experiments. In addition, donor variability should be
considered (Dern et al., 1966; Tzounakas et al., 2015).
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DISCUSSION
Conceptualization and Limitations
The feasibility of maintaining RBCs in a stable small-scale
perfusion bioreactor was clearly demonstrated here, and the
fluidized-bed was the most suitable design for perfusion since the
other tested designs did not allow to reach the requirements. It
enabled segregation of cells from the medium without additional
filters and back-pressure. With this platform, measurement
of on-line parameters and collection of extracellular samples
was made possible. The number of cells was minimized to
reduce biological sample size and the ECs were 10 times
diluted (hematocrit of 3.8 ± 0.9, n = 6). SAGM was
adapted to insure the same glucose-to-cell ratio (glucose
dilution by 10), whereas NaCl (osmolarity and ionic balance),
adenine (metabolism maintenance) and mannitol (membrane
stabilization) concentrations were kept constant. The main
reason for this change was the need to observe a detectable
extracellular consumption during the storage, and having a high
glucose-to-cell ratio could have influenced results in this regard.
Thus, mSAGM was used instead of SAGM.
Moreover, to avoid contamination at this stage of the
conceptualization of this small-scale perfusion bioreactor,
antibiotics (penicillin and streptomycin) were added, which
successfully prevented time-to-time abnormally high hemolysis
levels (contamination observed in initially stages of design, data
not shown). In a long-term view, the use of antibiotics would be
avoided by the employment of completely sterile materials and
environment.
Additionally, the efficiency of oxygen-depletion is important.
Argon flux may not be sufficient under these conditions to
ensure efficient O2 depletion (even though bioreactors and
reservoirs were under constant gas supply) and could explain the
partly muted differences between the gases tested. Therefore, the
integration of dissolved oxygen probes (e.g., from PreSens Gmbh,
presens.de) is an important step in the evolution of our system for
studying aerobic and anaerobic conditions.
Hemolysis and MVs
Regarding hemolysis and MVs, lower levels were observed under
the anaerobic conditions (the difference was significant for
hemolysis). This is consistent with our preliminary works and
with the hemolysis results found by Yoshida et al. (2007), Yoshida
and Shevkoplyas (2010). Since both hemolysis and MV levels
increase with storage duration (Hess et al., 2000; Greenwalt, 2006;
Yoshida et al., 2007; Rubin et al., 2013; Wagner et al., 2014), they
may be considered as the direct consequences of the storage-
induced cell damages and lower levels would therefore indicate
improved RBC conservation. Under this hypothesis, anaerobic
storage would appear as having a positive effect on RBC aging
processes, probably by lowering oxidative stress. Alternatively,
these hemolysis and microvesiculation phenomena might be
protective for the cells, getting rid of deleterious compounds
(Willekens et al., 2008; Delobel et al., 2012). MVs contain a level
of oxidized proteins that increases with storage duration (Delobel
et al., 2012), and therefore microvesiculation may act specifically
as a protection against oxidative damage. The decreased levels
under argon could point to both the disruption of these protective
mechanisms or the reduction of the actual cellular damages.
Metabolites
The extracellular glucose profiles (Figure 3A) showed a constant
decrease consistent with cell consumption. On the other hand,
extracellular lactate (Figure 3B), as the end-product of glycolysis,
accumulated until reaching a plateau and, and subsequently
continued to decrease slightly. A possible explanation may be the
presence of lactate dehydrogenase and its activity in the medium
at RT, because of higher hemolysis compared to cold storage.
However, we cannot exclude a shift of the metabolism that could
use pyruvate in other pathways.
The intracellular data are consistent with the literature
on ex vivo aging (D’Alessandro et al., 2015). The faster
depletion observed here is explained by high temperature, as
the bioreactors were run at RT. Moreover, in spite of an
expected extracellular glucose level, the glycolytic metabolites
were impoverished, which is also the case in cold storage
(Gevi et al., 2012; Roback et al., 2014). Interestingly, the
accumulation of phosphoenolpyruvate and decrease of pyruvate
during bioreactor storage could be explained by a reduced activity
of pyruvate kinase. Delobel et al. reported that this enzyme was
carbonylated during cold storage of RBCs and that the absence
of it at the end of the storage could be explained by protein
relocation or elimination through microvesiculation (Delobel
et al., 2012, 2016).
Comparing aerobic vs. anaerobic storage, the extracellular
glucose consumption appeared to be lower under argon (though
not significant), whereas lactate production was equivalent.
Moreover, the end-point metabolomics does not allow for
distinguishing clear effects since several metabolites were already
depleted. These results are not consistent with the observations
of Yoshida’s and Zolla’s groups (Yoshida et al., 2007, 2008;
Dumont et al., 2009, 2016; Yoshida and Shevkoplyas, 2010;
D’Alessandro et al., 2013, 2015). They indeed reported both
higher glucose consumption and higher lactate production under
oxygen-depletion, as well as a general increase in glycolysis as
O2 partly inhibits it. It has been proposed that oxygen depletion
forces the hemoglobin contained in RBCs into its deoxygenated
state (Lewis et al., 2009; Castagnola et al., 2010). It results in (i)
the increased hemoglobin affinity for protons, leading to higher
pH, and therefore increased phosphofructokinase (the glycolysis
rate-limiting enzyme) activity; (ii) increased hemoglobin affinity
for 2,3-DPG and ATP, and thus reduced inhibition of
phosphofructokinase; (iii) increased hemoglobin affinity for the
band 3 protein causing release of phosphofructokinase and other
glycolytic enzymes. Hence, hypoxia induces a shift from the
PPP to the glycolysis (Kinoshita et al., 2007; Rogers et al., 2009;
Dumont et al., 2016). Under these conditions, the recycling
capacity of antioxidants like glutathione is lowered because
the PPP does not produce enough NADPH. A shunt to the
non-oxidative PPP (known in case of ribose 5-phosphate need
and not NADPH, Stryer, 1992) could be one explanation of
the differences observed under our bioreactor working at RT
(Figure 5).
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These interpretations go beyond the aim of this project
and will require a more advanced system and replicates.
However, they point out the role of such bioreactors and their
improvements. Monitoring and controlling the pH appear thus
important. The integration of pH (and potassium) electrodes and
O2 probes are already planned for the future development, and
will bring insights on storage lesions.
CONCLUSIONS
A small-scale perfusion bioreactor of RBCs was designed and has
been developed to limit the quantity of cells used, to constantly
segregate RBCs from the medium without filters and to enable
the setup of different storage or environmental conditions. The
development reached so far operates at a flow rate of 8.5
µL/min, includes gas supply and runs over a 14-day period
at RT. Moreover, the design allows for easy sampling of the
extracellular medium and cells thanks to the fluidized bed system.
Remarkably, it enables us to change the bioreactors medium in a
dynamic manner (since it is permanently separated from cells).
Beyond the cell segregation and the simplified monitoring of
extracellular compartment, the principle was proven by studying
hemolysis, microvesiculation, and extracellular and intracellular
metabolites. The targetedmetabolomic approach clearly reported
the depletion of glycolytic, PPP and energy metabolites. Even
though the RBC metabolism under aerobic and anaerobic
conditions has to be further studied kinetically, this approach
appears more than suitable to study RBCs (Prudent et al., 2014).
It is able to challenge RBCs andmimic their pathways in response
to different stimuli. For instance, the combination of antioxidants
and anaerobic conditions could be investigated in order to take
advantage of them (D’Alessandro et al., 2013; Pallotta et al., 2014).
Further bioreactor development will employ new probes for
on-linemonitoring and consider other gases (or gas composition,
Dumont et al., 2016) and AS. An O2-probe to better control
depletion efficiency is currently under implementation. This
small-scale perfusion bioreactor potentially gives access to a high
number of difficult-to-obtain parameters (on-line or off-line) and
could be coupled to other tools such as NMR (Gmati et al., 2005).
It is of high importance to deeper understand this complex cell
and the signaling involved under various conditions.
This fundamental approach is not only of importance
in transfusion medicine since such bioreactor enable the
comparison of different AS formulation and metabolic supply,
but also for understanding RBC senescence (in whole blood,
for instance) including different metabolic pathways, protein
modification, microvesiculation, defense mechanisms and so
forth. The goal of such a system is to provide innovative
strategies to reconsider RBC storage. This development gives
new insight in the way of handling RBCs in an open
system.
AUTHOR CONTRIBUTIONS
MP initiated the project and the conception, reviewed
improvements, analyzed data and wrote the article. SH
made the first developments and designed the fluidized-bed
bioreactor. AR improved the bioreactor and fixed hemolysis
issues. NP and FS carried out experiments and improved the
setup and quantification of metabolites. All of them contributed
to the writing of the manuscript. LM and BR ran metabolomic
experiments. MA ran statistical analysis and reviewed data. JT
and NL reviewed the data and the manuscript. All the authors
read and approved the final manuscript.
ACKNOWLEDGMENTS
They authors thank Mr. Crettaz and Dr. Delobel for discussions
and supports, and colleagues from preparation unit for EC
supply.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmolb.
2016.00011
REFERENCES
Antonelou, M. H., Kriebardis, A. G., and Papassideri, I. S. (2010). Aging and death
signalling in mature red cells: from basic science to transfusion practice. Blood
Transfus. 8, S39–S47. doi: 10.2450/2010.007s
Benjamin, R. J., and Dodd, R. Y. (2008). Red-cell storage and complications of
cardiac surgery. New Engl. J. Med. 358, 2840–2841. doi: 10.1056/NEJMc080874
Bennett-Guerrero, E., Veldman, T. H., Doctor, A., Telen, M. J., Ortel, T. L., Reid, T.
S., et al. (2007). Evolution of adverse changes in stored RBCs. Proc. Natl. Acad.
Sci. U.S.A. 104, 17063–17068. doi: 10.1073/pnas.0708160104
Ben-Tchavtchavadze, M., Chen, J., Perrier, M., and Jolicoeur, M. (2010).
A noninvasive technique for the measurement of the energetic state
of free-suspension mammalian cells. Biotechnol. Prog. 26, 532–541. doi:
10.1002/btpr.333
Bosman, G., Lasonder, E., Luten, M., Roerdinkholder-Stoelwinder, B., Novotny,
V. M. J., Bos, H., et al. (2008). The proteome of red cell membranes and
vesicles during storage in blood bank conditions. Transfusion 48, 827–835. doi:
10.1111/j.1537-2995.2007.01630.x
Bruce, L. J., Beckmann, R., Ribeiro, M. L., Peters, L. L., Chasis, J. A., Delaunay, J.,
et al. (2003). A band 3-based macrocomplex of integral and peripheral proteins
in the RBC membrane. Blood 101, 4180–4188. doi: 10.1182/blood-2002-09-
2824
Butler, M. (2005). Animal cell cultures: recent achievements and perspectives in
the production of biopharmaceuticals.Appl. Microbiol. Biotechnol. 68, 283–291.
doi: 10.1007/s00253-005-1980-8
Castagnola, M., Messana, I., Sanna, M. T., and Giardina, B. (2010). Oxygen-linked
modulation of erythrocyte metabolism: state of the art. Blood Transfus. 8,
S53–S58. doi: 10.2450/2010.009s
Chu, H. Y., Breite, A., Ciraolo, P., Franco, R. S., and Low, P. S. (2008).
Characterization of the deoxyhemoglobin binding site on human erythrocyte
band 3: implications for O-2 regulation of erythrocyte properties. Blood 111,
932–938. doi: 10.1182/blood-2007-07-100180
Collins, P. C., Nielsen, L. K., Patel, S. D., Papoutsakis, E. T., and Miller, W. M.
(1998). Characterization of hematopoietic cell expansion, oxygen uptake, and
glycolysis in a controlled, stirred-tank bioreactor system. Biotechnol. Prog. 14,
466–472. doi: 10.1021/bp980032e
Frontiers in Molecular Biosciences | www.frontiersin.org 9 March 2016 | Volume 3 | Article 11
Prudent et al. Fluidized-Bed Erythrocyte Bioreactor
D’Alessandro, A., Gevi, F., and Zolla, L. (2013). Red blood cell metabolism
under prolonged anaerobic storage. Mol. Biosyst. 9, 1196–1209. doi:
10.1039/c3mb25575a
D’Alessandro, A., Kriebardis, A. G., Rinalducci, S., Antonelou, M. H., Hansen,
K. C., Papassideri, I. S., et al. (2015). An update on red blood cell storage
lesions, as gleaned through biochemistry and omics technologies. Transfusion
55, 205–219. doi: 10.1111/trf.12804
D’Alessandro, A., and Zolla, L. (2013). Biochemistry of red blood cell aging in vivo
and storage lesions. Hematol. Educ. 7, 1–8.
D’Amici, G. M., Rinalducci, S., and Zolla, L. (2007). Proteomic analysis of RBC
membrane protein degradation during blood storage. J. Proteome Res. 6,
3242–3255. doi: 10.1021/pr070179d
Danesh, A., Inglis, H. C., Jackman, R. P., Wu, S., Deng, X., Muench, M. O.,
et al. (2014). Exosomes from red blood cell units bind to monocytes and
induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood
123, 687–696. doi: 10.1182/blood-2013-10-530469
Delobel, J., Prudent, M., Rubin, O., Crettaz, D., Tissot, J.-D., and Lion, N. (2012).
Subcellular fractionation of stored red blood cells reveals a compartment-
based protein carbonylation evolution. J. Proteomics 76, 181–193. doi:
10.1016/j.jprot.2012.05.004
Delobel, J., Prudent, M., Tissot, J. D., and Lion, N. (2016). Proteomics of the red
blood cells carbonylome during blood banking of erythrocyte concentrates.
Proteomics Clin. Appl. 10, 257–266. doi: 10.1002/prca.201500074
Deonikar, P., and Kavdia, M. (2010). Extracellular diffusion and permeability
effects on NO-RBCs interactions using an experimental and theoretical model.
Microvasc. Res. 79, 47–55. doi: 10.1016/j.mvr.2009.10.002
Dern, R. J., Gwinn, R. P., and Wiorkows, J. J. (1966). Studies on preservation of
human blood.I. Variability in erythrocyte storage characteristics among healthy
donors. J. Lab. Clin. Med. 67, 955–965.
Dumaswala, U. J., Wilson, M. J., Wu, Y. L., Wykle, J., Zhuo, L., Douglass, L. M.,
et al. (2000). Glutathione loading prevents free radical injury in red blood cells
after storage. Free Radic. Res. 33, 517–529. doi: 10.1080/10715760000301061
Dumont, L. J., D’Alessandro, A., Szczepiorkowski, Z. M., and Yoshida, T.
(2016). CO2-dependent metabolic modulation in red blood cells stored under
anaerobic conditions. Transfusion 56, 392–403. doi: 10.1111/trf.13364
Dumont, L. J., Yoshida, T., and AuBuchon, J. P. (2009). Anaerobic storage of red
blood cells in a novel additive solution improves in vivo recovery. Transfusion
49, 458–464. doi: 10.1111/j.1537-2995.2008.02038.x
Flatt, J. F., Bawazir, W. M., and Bruce, L. J. (2014). The involvement of cation
leaks in the storage lesion of red blood cells. Front. Physiol. 5:214. doi:
10.3389/fphys.2014.00214
Gevi, F., D’Alessandro, A., Rinalducci, S., and Zolla, L. (2012). Alterations of red
blood cell metabolome during cold liquid storage of erythrocyte concentrates
in CPD-SAGM. J. Proteomics 76, 168–180. doi: 10.1016/j.jprot.2012.03.012
Gmati, D., Chen, J. K., and Jolicoeur, M. (2005). Development of a small-scale
bioreactor: application to in vivo NMR measurement. Biotechnol. Bioeng. 89,
138–147. doi: 10.1002/bit.20293
Greenwalt, T. J. (2006). The how and why of exocytic vesicles. Transfusion 46,
143–152. doi: 10.1111/j.1537-2995.2006.00692.x
Harboe, M. (1959). A method for determination of hemoglobin in plasma by
near-ultraviolet spectrophotometry. Scand. J. Clin. Lab. Invest. 11, 66–70. doi:
10.3109/00365515909060410
Hess, J. R. (2006). An update on solutions for red cell storage. Vox Sang. 91, 13–19.
doi: 10.1111/j.1423-0410.2006.00778.x
Hess, J. R., and Greenwalt, T. G. (2002). Storage of red blood cells: new approaches.
Transfus. Med. Rev. 16, 283–295. doi: 10.1053/tmrv.2002.35212
Hess, J. R., Lippert, L. E., Derse-Anthony, C. P., Hill, H. R., Oliver, C. K., Rugg,
N., et al. (2000). The effects of phosphate, pH, and AS volume on RBCs stored
in saline-adenine-glucose-mannitol solutions. Transfusion 40, 1000–1006. doi:
10.1046/j.1537-2995.2000.40081000.x
Hod, E. A., Brittenham, G. M., Billote, G. B., Francis, R. O., Ginzburg, Y. Z.,
Hendrickson, J. E., et al. (2011). Transfusion of human volunteers with older,
stored red blood cells produces extravascular hemolysis and circulating non-
transferrin-bound iron. Blood 118, 6675–6682. doi: 10.1182/blood-2011-08-
371849
Hod, E. A., and Spitalnik, S. L. (2012). Stored red blood cell transfusions: iron,
inflammation, immunity, and infection. Transfus. Clin. Biol. 19, 84–89. doi:
10.1016/j.tracli.2012.04.001
Housler, G. J., Miki, T., Schmelzer, E., Pekor, C., Zhang, X. K., Kang, L., et al. (2012).
Compartmental hollow fiber capillary membrane-based bioreactor technology
for in vitro studies on red blood cell lineage direction of hematopoietic stem
cells. Tissue Eng. C Methods 18, 133–142. doi: 10.1089/ten.tec.2011.0305
Jy, W., Johansen, M. E., Bidot, C., Horstman, L. L., and Ahn, Y. S. (2013). Red cell-
derived microparticles (RMP) as haemostatic agent. Thromb. Haemost. 110,
751–760. doi: 10.1160/TH12-12-0941
Kinoshita, A., Tsukada, K., Soga, T., Hishiki, T., Ueno, Y., Nakayama, Y., et al.
(2007). Roles of hemoglobin allostery in hypoxia-induced metabolic alterations
in erythrocytes - Simulation and its verification by metabolome analysis. J. Biol.
Chem. 282, 10731–10741. doi: 10.1074/jbc.M610717200
Koch, C. G., Li, L., Sessler, D. I., Figueroa, P., Hoeltge, G. A., Mihaljevic, T., et al.
(2008). Duration of red-cell storage and complications after cardiac surgery.
New Engl. J. Med. 358, 1229–1239. doi: 10.1056/NEJMoa070403
Lacroix, J., Hebert, P. C., Fergusson, D. A., Tinmouth, A., Cook, D. J., Marshall, J.
C., et al. (2015). Age of transfused blood in critically Ill adults.New Engl. J. Med.
372, 1410–1418. doi: 10.1056/NEJMoa1500704
Lewis, I. A., Campanella, M. E., Markley, J. L., and Low, P. S. (2009). Role of band 3
in regulating metabolic flux of red blood cells. Proc. Natl. Acad. Sci. U.S.A. 106,
18515–18520. doi: 10.1073/pnas.0905999106
Liu, Y., Liu, T. Q., Fan, X. B., Ma, X. H., and Cui, Z. F. (2006). Ex vivo expansion
of hematopoietic stem cells derived from umbilical cord blood in rotating wall
vessel. J. Biotechnol. 124, 592–601. doi: 10.1016/j.jbiotec.2006.01.020
McCullough, J. (2013). Red cell storage: does duration matter? Blood 121,
1491–1492. doi: 10.1182/blood-2013-01-475988
Nishino, T., Yachie-Kinoshita, A., Hirayama, A., Soga, T., Suematsu, M., and
Tomita, M. (2009). In silico modeling and metabolome analysis of long-stored
erythrocytes to improve blood storage methods. J. Biotechnol. 144, 212–223.
doi: 10.1016/j.jbiotec.2009.08.010
Nishino, T., Yachie-Kinoshita, A., Hirayama, A., Soga, T., Suematsu, M., and
Tomita, M. (2013). Dynamic simulation and metabolome analysis of long-term
erythrocyte storage in adenine-guanosine solution. PLoS ONE 8:e71060. doi:
10.1371/journal.pone.0071060
Paglia, G., Bordbar, A., Magnúsdóttir, K. W., Palsson, M., Rolfsson, S., Hansen, M.,
et al. (2014). Systems biology analysis of stored red blood cells in SAGM reveals
three disctinct metabolic states. Transfusion 54, 48A–49A.
Pallotta, V., Gevi, F., D’Alessandro, A., and Zolla, L. (2014). Storing red blood cells
with vitamin C and N-acetylcysteine prevents oxidative stress-related lesions:
a metabolomics overview. Blood Transfus. 12, 367–387. doi: 10.2450/2014.
0266-13
Pallotta, V., Rinalducci, S., and Zolla, L. (2015). Red blood cell storage affects the
stability of cytosolic native protein complexes. Transfusion 55, 1927–1936. doi:
10.1111/trf.13079
Prudent, M., Rochat, B., Marvin, L., Stauber, F., Tissot, J. D., and Lion, N. (2014).
Targeted Metabolomics of SAGM red blood cell storage. Clin. Lab. 60, S3–S3.
Prudent, M., Tissot, J. D., and Lion, N. (2011). Proteomics of blood and
derived products: what’s next? Expert Rev. Proteomics 8, 717–737. doi:
10.1586/epr.11.58
Prudent, M., Tissot, J. D., and Lion, N. (2015). In vitro assays and clinical trials
in red blood cell aging: lost in translation. Transfus. Apheresis Sci. 52, 270–276.
doi: 10.1016/j.transci.2015.04.006
Ratcliffe, E., Glen, K. E., Workman, V. L., Stacey, A. J., and Thomas, R. J. (2012). A
novel automated bioreactor for scalable process optimisation of haematopoietic
stem cell culture. J. Biotechnol. 161, 387–390. doi: 10.1016/j.jbiotec.2012.
06.025
Rinalducci, S., D’Amici, G. M., Blasi, B., Vaglio, S., Grazzini, G., and Zolla,
L. (2011). Peroxiredoxin-2 as a candidate biomarker to test oxidative stress
levels of stored red blood cells under blood bank conditions. Transfusion 51,
1439–1449. doi: 10.1111/j.1537-2995.2010.03032.x
Roback, J. D., Josephson, C. D., Waller, E. K., Newman, J. L., Karatela, S., Uppal, K.,
et al. (2014). Metabolomics of ADSOL (AS-1) red blood cell storage. Transfus.
Med. Rev. 28, 41–55. doi: 10.1016/j.tmrv.2014.01.003
Rogers, S. C., Said, A., Corcuera, D., McLaughlin, D., Kell, P., and Doctor, A.
(2009). Hypoxia limits antioxidant capacity in red blood cells by altering
glycolytic pathway dominance. FASEB J. 23, 3159–3170. doi: 10.1096/fj.09-
130666
Rubin, O., Crettaz, D., Canellini, G., Tissot, J. D., and Lion, N. (2008).
Microparticles in stored red blood cells: an approach using flow cytometry
Frontiers in Molecular Biosciences | www.frontiersin.org 10 March 2016 | Volume 3 | Article 11
Prudent et al. Fluidized-Bed Erythrocyte Bioreactor
and proteomic tools. Vox Sang. 95, 288–297. doi: 10.1111/j.1423-0410.2008.
01101.x
Rubin, O., Delobel, J., Prudent, M., Lion, N., Kohl, K., Tucker, E. I., et al.
(2013). Red blood cell-derived microparticles isolated from blood units
initiate and propagate thrombin generation. Transfusion 53, 1744–1754. doi:
10.1111/trf.12008
Sparrow, R. L., Sran, A., Healey, G., Veale, M. F., and Norris, P. J. (2014). In
vitro measures of membrane changes reveal differences between red blood
cells stored in saline-adenine-glucose-mannitol and AS-1 additive solutions: a
paired study. Transfusion 54, 560–568. doi: 10.1111/trf.12344
Steiner, M. E., Ness, P. M., Assmann, S. F., Triulzi, D. J., Sloan, S. R., Delaney,
M., et al. (2015). Effects of red-cell storage duration on patients undergoing
cardiac surgery. New Engl. J. Med. 372, 1419–1429. doi: 10.1056/NEJMoa14
14219
Stryer, L. (1992). La Biochimie de Lubert Stryer. Paris: Flammarion.
Timmins, N. E., Athanasas, S., Gunther, M., Buntine, P., and Nielsen, L. K. (2011).
Ultra-high-yield manufacture of red blood cells from hematopoietic stem cells.
Tissue Eng. C Methods 17, 1131–1137. doi: 10.1089/ten.tec.2011.0207
Tinmouth, A., and Chin-Yee, I. (2001). The clinical consequences of the red
cell storage lesion. Transfus. Med. Rev. 15, 91–107. doi: 10.1053/tmrv.2001.
22613
Tzounakas, V. L., Georgatzakou, H. T., Kriebardis, A. G., Papageorgiou, E. G.,
Stamoulis, K. E., Foudoulaki-Paparizos, L. E., et al. (2015). Uric acid variation
among regular blood donors is indicative of red blood cell susceptibility to
storage lesionmarkers: a new hypothesis tested.Transfusion 55, 2659–2671. doi:
10.1111/trf.13211
van de Watering, L. (2014). More data on red blood cell storage could clarify
confusing clinical outcomes. Transfusion 54, 501–502. doi: 10.1111/trf.12581
van de Watering, L. M. G. (2013a). Age of blood: does older blood
yield poorer outcomes? Curr. Opin. Hematol. 20, 526–532. doi:
10.1097/MOH.0b013e328365aa3a
van de Watering, L. M. G. (2013b). Effects of red blood cell storage
in heavily transfused patients. Curr. Opin. Anesthesio. 26, 204–207. doi:
10.1097/ACO.0b013e32835e7408
Wagner, T., Pabst, M. A., Leitinger, G., Reiter, U., Kozma, N., Lanzer, G.,
et al. (2014). Impact of constant storage temperatures and multiple warming
cycles on the quality of stored red blood cells. Vox Sang. 106, 45–54. doi:
10.1111/vox.12074
Willekens, F. L. A., Werre, J. M., Groenen-Dop, Y. A. M., Roerdinkholder-
Stoelwinder, B., de Pauw, B., and Bosman, G. (2008). Erythrocyte vesiculation: a
self-protective mechanism? Br. J. Haematol. 141, 549–556. doi: 10.1111/j.1365-
2141.2008.07055.x
Yoshida, T., AuBuchon, J. P., Dumont, L. J., Gorham, J. D., Gifford, S. C.,
Foster, K. Y., et al. (2008). The effects of additive solution pH and metabolic
rejuvenation on anaerobic storage of red cells. Transfusion 48, 2096–2105. doi:
10.1111/j.1537-2995.2008.01812.x
Yoshida, T., AuBuchon, J. P., Tryzelaar, L., Foster, K. Y., and Bitensky, M. W.
(2007). Extended storage of red blood cells under anaerobic conditions. Vox
Sang. 92, 22–31. doi: 10.1111/j.1423-0410.2006.00860.x
Yoshida, T., and Shevkoplyas, S. S. (2010). Anaerobic storage of red blood cells.
Blood Transfus. 8, 220–236. doi: 10.2450/2010.0022-10
Zhong, J.-J. (2010). Recent advances in bioreactor engineering. Korean J. Chem.
Eng. 27, 1035–1041. doi: 10.1007/s11814-010-0277-5
Zimring, J. C. (2013). Fresh versus old blood: are there differences and
do they matter? Hematol. Am. Soc. Hematol. Educ. Progr. 651–655. doi:
10.1182/asheducation-2013.1.651
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer (MA) and Handling Editor declared their shared affiliation,
and the Handling Editor states that the process nevertheless met the standards of
a fair and objective review.
Copyright © 2016 Prudent, Stauber, Rapin, Hallen, Pham, Abonnenc, Marvin,
Rochat, Tissot and Lion. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Molecular Biosciences | www.frontiersin.org 11 March 2016 | Volume 3 | Article 11
